Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant
NCT04312789 · Ayman Saad · PHASE2 · withdrawn · last registry update 2021-12-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Drug availability” | – | Registry record, Ayman Saad |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MPL within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-11-07Also stopped (terminated): H. Lee Moffitt Cancer Center and Research Institute, Eltrombopag (NCT01286038)
- 2022-08-08Phase 3 first posted: AO GENERIUM, GNR-069 (NCT05492409)
- 2022-07-22Also stopped (terminated): Roswell Park Cancer Institute, eltrombopag olamine (NCT01550185)
- 2022-07-20Phase 3 first posted: The First Affiliated Hospital of Soochow University, Eltrombopag 25 MG Oral Tablet + Supportive care (NCT05466201)
- 2022-06-30Phase 3 first posted: Peking University People's Hospital, all-trans retinoic acid + Eltrombopag (NCT05438875)
- 2022-05-11Phase 3 first posted: Sobi, Inc., Avatrombopag Oral Tablet (NCT05369208)
- 2022-04-13Phase 3 first posted: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, romiplostim plus dexamethasone + Dexamethasone (NCT05325593)
- 2022-03-02Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., Hetrombopag + Matching placebo (NCT05261646)
- 2022-02-02Phase 3 first posted: AO GENERIUM, GNR-069 + Nplate (NCT05220878)
- 2021-11-24Results posted on the registry: Sobi, Inc., Avatrombopag + Placebo Oral Tablet (NCT03471078)
- 2021-10-22Also stopped (withdrawn): Sobi, Inc., Avatrombopag 20 mg Oral Tablet (NCT05046327)
- 2021-09-21Results posted on the registry: M.D. Anderson Cancer Center, AMG 531 + Rituximab (NCT00299182)
- 2021-09-16Phase 3 first posted: Sobi, Inc., Avatrombopag 20 mg Oral Tablet (NCT05046327)
- 2021-08-05Results posted on the registry: Abramson Cancer Center at Penn Medicine, Eltrombopag (NCT01113502)
- 2021-08-05Also stopped (terminated): Abramson Cancer Center at Penn Medicine, Eltrombopag (NCT01113502)
- 2021-07-14Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., Hetrombopag Olamine + Placebo (NCT04961710)
- 2021-06-07Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Combined use of TPO-RAs with low-dose anti-CD20 antibody + The best available therapy (NCT04915482)
- 2021-03-18Also stopped (terminated): Shionogi, Placebo + Lusutrombopag (NCT01054443)
- 2021-02-26Results posted on the registry: Shionogi, Lusutrombopag (NCT01129024)
- 2021-02-26Also stopped (terminated): Shionogi, Lusutrombopag (NCT01129024)
- 2021-02-24Results posted on the registry: Shionogi, Placebo + Lusutrombopag (NCT01054443)
- 2021-02-15Results posted on the registry: Kyowa Kirin Korea Co., Ltd., AMG531 (NCT02094417)
- 2021-02-08Also stopped (terminated): Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH, Standard chemotherapy + Romiplostim (NCT03622931)
- 2021-01-28Phase 3 first posted: Peking Union Medical College Hospital, Avatrombopag 20 MG (NCT04728789)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision